Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens
Arcus Biosciences shares dropped 9.3% to $21.05 Thursday after Morgan Stanley downgraded the stock and cut its price target to $20. The company highlighted a February data update and a Jan. 14 J.P. Morgan conference slot. BlackRock disclosed a 10.4% stake as of Dec. 31. President Juan C. Jaen reported selling 31,823 shares on Jan. 5 under a pre-set trading plan.